ArticleJournal of the National Cancer Institute2021
Age Is Just a Number: Considerations for Older Adults in Cancer Clinical Trials.
Article in Journal of the National Cancer Institute, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Inclusion, characteristics, and reporting of older patients in recent registration trials for DLBCL.Blood advances · 2026Pooled it
- Temporal changes in characteristics and external validity of randomized controlled trials in older people from 2012 to 2019.BMC geriatrics · 2023Pooled it
- Integration of geriatric assessment-guided care plan modifications and interventions into clinical paths of older adults with cancer (GORILLA): a feasibility approach.European geriatric medicine · 2026Article
- Closing the gap of older adult recruitment to cancer clinical trials: a scoping review.BMC cancer · 2026Article
- The ESMO/SIOG Cancer in the Elderly Working Group pragmatic strategies for clinical trial designs and endpoints in older adults with cancer.ESMO open · 2026Review
- Efficacy of First-Line EGFR-TKI Treatment in Octogenarians with Lung Adenocarcinoma and Common EGFR Mutations.Clinical interventions in aging · 2026Article
- Article
- Article
- Aging-Related Mechanisms Underlying Carcinogenesis: Therapeutic Opportunities.Aging and disease · 2025Review
- The WHO global landscape of cancer clinical trials.Nature medicine · 2025Review
- Effects of aging on anticancer therapy in murine cancer models.Cancer metastasis reviews · 2025Review
- What Is Ailing Oncology Clinical Trials? Can We Fix Them?Current oncology (Toronto, Ont.) · 2024Review
- Diversity in Oncology Clinical Trials: Current Landscape for Industry-Sponsored Clinical Trials in Asia.Oncology and therapy · 2024Article
- Reporting of older subgroups in registration breast cancer trials 2012-2021.Breast cancer research and treatment · 2023Review
- Article
- A multinational investigation of healthcare needs, preferences, and expectations in supportive cancer care: co-creating the LifeChamps digital platform.Journal of cancer survivorship : research and practice · 2023Article
- Eligibility criteria in clinical trials in breast cancer: a cohort study.BMC medicine · 2023Article
- Factors affecting the recruitment of Hispanic/Latinx American older adults in clinical trials in the United States: A scoping review.Journal of the American Geriatrics Society · 2023Article
- Article
- Patients at the Heart of the Scientific Dialogue: An Industry Perspective.Oncology and therapy · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Older adults continue to be underrepresented in cancer clinical trials, despite most cancer occurrence peaking in the later decades of life. Consequently, diagnostic and management strategies are commonly extrapolated from data on younger patients, thus challenging the delivery of informed cancer care in this patient population. Several recommendations and calls to action have been released by cancer societies, advocacy organizations, and regulatory agencies to guide inclusion of older adults in clinical trials. Effective implementation, however, requires awareness and close collaboration between all stakeholders involved in the clinical trial journey. We herein provide insights and experience from a drug developer on key considerations to optimize participation and retention of older adults in cancer clinical trials and discuss those under 4 key domains: trial eligibility and design, assessments and endpoints, patients and oncologists, and data reporting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.